Novotech Executive and Leadership Team

Vivek Kapoor, the Group Chief Financial Officer at Novotech, directs all global fiscal planning and capital allocation strategies. Overseeing the financial health of the organization, the Group Chief Financial Officer ensures robust investment in clinical research infrastructure across international markets. This leadership role involves managing complex budgetary frameworks to support the rapid expansion of biotech partnerships. By optimizing resource distribution, Vivek Kapoor directly impacts the long-term scalability of the clinical research organization. Furthermore, Kapoor maintains rigorous oversight of fiscal reporting standards, ensuring transparency for stakeholders while driving sustainable growth. Through precise financial modeling, the Group Chief Financial Officer secures the necessary capital to fuel innovation in therapeutic development, ultimately strengthening the market position of the firm within the competitive global CRO landscape.

Joseph Dumais, the President at Novotech, directs the overarching corporate strategy and operational execution across all global business units. Overseeing the alignment of departmental goals with the mission of accelerating therapeutic development, the President ensures that the organization maintains its competitive edge in the CRO industry. This leadership role involves managing high-level relationships with biotech partners and driving the expansion of service capabilities into new geographic markets. By fostering a culture of operational excellence, Joseph Dumais directly impacts the efficiency and quality of clinical research delivery. Furthermore, Dumais coordinates with the executive team to implement long-term growth initiatives that support the development of novel therapeutics. Through decisive leadership, the President secures the firm's position as a premier partner for biotech companies seeking to navigate the complexities of modern clinical research.

Melinda Borrelli, the Head of Medical Office Chief & Chief Marketing Officer, Operations at Novotech, directs the integration of clinical expertise with global brand positioning. Overseeing the alignment of medical standards with market outreach, the Head of Medical Office Chief & Chief Marketing Officer, Operations ensures that biotech partners receive clear communication regarding complex research capabilities. This leadership role involves architecting strategic campaigns that highlight the firm's proficiency in accelerating therapeutic development. By bridging the gap between technical medical operations and commercial growth, Melinda Borrelli directly influences the acquisition of new clinical trials. Additionally, Borrelli manages the operational efficiency of marketing initiatives across diverse geographic regions. Through this dual focus, the Head of Medical Office Chief & Chief Marketing Officer, Operations drives brand authority while maintaining the highest standards of clinical excellence.

Kristin Brown, the Chief Legal Officer at Novotech, directs all corporate governance, regulatory compliance, and contractual frameworks. Overseeing the legal integrity of global clinical trials, the Chief Legal Officer ensures adherence to international health standards and local jurisdictional requirements. This leadership role involves mitigating risk during complex biotech partnerships and protecting intellectual property throughout the drug development lifecycle. By providing strategic counsel to the executive board, Kristin Brown directly supports the secure expansion of clinical research operations. Furthermore, Brown manages the legal aspects of cross-border collaborations, ensuring seamless integration of services across diverse regulatory environments. Through meticulous oversight of compliance protocols, the Chief Legal Officer maintains the reputation of the firm as a trusted partner in the global development of advanced and novel therapeutics.

Judith Ng-Cashin, the Chief Medical Officer at Novotech, directs the scientific strategy and clinical oversight for all therapeutic development programs. Overseeing the medical integrity of complex trials, the Chief Medical Officer ensures that every study meets rigorous safety and efficacy benchmarks. This leadership role involves guiding clinical teams through the intricacies of drug development, from early-phase research to late-stage trials. By fostering collaboration with biotech innovators, Judith Ng-Cashin directly accelerates the delivery of novel treatments to patients worldwide. Furthermore, Ng-Cashin provides critical medical expertise to the executive team, shaping the long-term research roadmap of the organization. Through the application of advanced clinical knowledge, the Chief Medical Officer drives the success of diverse therapeutic portfolios, ensuring that the firm remains at the forefront of global medical innovation.